Table 2.
Analyses |
Sample 1 (NACC
&
ROS/MAP) |
NACC | ROS/MAP |
Sample 2 (ADNI
&
Prevent-AD) |
||||
---|---|---|---|---|---|---|---|---|
β (95% CI) | p | β (95% CI) | p | β (95% CI) | p | β (95% CI) | p | |
Three-way interaction: | ||||||||
Sex × APOE ε2 (vs. ε3/ε3) × time | 0.097 (0.023 – 0.172) | .01 | 0.081 (0.010 – 0.152) | .02 | 0.127 (−0.069 – 0.323) | .20 | 0.195 (0.006 – 0.385) | .04 |
Sex-stratified two-way interactions: | ||||||||
APOE ε2 (vs. ε3/ε3) × time in men | 0.096 (0.037 – 0.155) | .001 | 0.074 (0.020 – 0.128) | .008 | 0.149 (−0.022 – 0.319) | .09 | 0.093 (−0.056 – 0.243) | .22 |
APOE ε2 (vs. ε3/ε3) × time in women | −0.001 (−0.044 – 0.043) | .97 | −0.008 (−0.051 – 0.035) | .71 | 0.012 (0.089 – 0.114) | .81 | −0.104 (−0.228 – 0.020) | .10 |
Genotype-stratified two-way interaction: | ||||||||
Male sex × time in APOE ε2 carriers | 0.120 (0.051 – 0.190) | .001 | 0.095 (0.028 – 0.161) | .005 | 0.191 (0.012 – 0.371) | .04 | 0.160 (−0.002 – 0.321) | .05 |
Male sex × time in APOE ε3/ε3 carriers | −0.000 (−0.031 – 0.030) | .99 | −0.005 (−0.033 – 0.024) | .75 | 0.038 (−0.044 – 0.121) | .36 | −0.009 (−0.091 – 0.074) | .84 |
NACC: National Alzheimer’s Coordinating Center
ROS: Religious Orders Study
MAP: Memory Aging Project
ADNI: Alzheimer’s Disease Neuroimaging Initiative
Prevent-AD: Pre-symptomatic Evaluation of Experimental or Novel Treatments for Alzheimer Disease
CI: confidence interval